Premenstrual syndrome (PMS) refers to a range of physical, emotional, and behavioural symptoms that typically occur in the week or two before your period starts and ease once bleeding begins. These can include bloating, breast tenderness, headaches, mood changes, irritability, or fatigue. For many women, symptoms are mild and manageable, but for others they significantly affect daily life.
Premenstrual dysphoric disorder (PMDD) is a more severe form involving intense mood symptoms such as marked depression, anxiety, irritability, or mood swings that cause serious problems with work, relationships, or other areas of functioning. It follows the same cyclical pattern but has a greater impact.
Why it matters
Many women experience cyclical symptoms, yet it can take time to get the right support. Qualitative accounts describe multiple appointments before the link to the menstrual cycle is properly explored, especially when mood symptoms are prominent. This can lead to frustration, repeated visits, and effects on work, relationships, and wellbeing. NHS data does not always capture PMDD clearly, which can limit service planning.
How medicines can affect symptoms
Hormonal contraceptives or other treatments may change or suppress ovulation, making the pattern less obvious. Antidepressants or anxiety medicines can dampen mood swings, while painkillers may mask physical clues. If you take medicines from different specialists, the full picture may not be clear without careful discussion of your cycle. This is not about the medicines being “wrong,” but about ensuring the cyclical nature is still considered.
During pregnancy and after birth
Symptoms often improve during pregnancy because there is no ovulation. Some women with a history of severe premenstrual issues report increased sensitivity to mood changes postnatally. Perinatal care encourages a full history, but experiences vary.
What can help
Keeping a daily symptom record over at least two cycles is a key step recommended in guidance. This helps show the timing and pattern. Talk to your GP about options, including lifestyle changes, talking therapies, or specific treatments. Public awareness is growing, and the Women’s Health Strategy highlights menstrual health as a priority.
System watchpoints
Research samples are often limited, and certain groups (adolescents, women with long-term conditions) are underrepresented. Apps vary in quality and may not connect well with NHS records.
Care can feel fragmented across primary care, gynaecology, and mental health. Clearer pathways and better integration of tracking tools are areas for improvement.
Questions for reflection
- Did describing the cyclical nature of symptoms feel straightforward when seeking help?
- Did any medicines for other issues change how your symptoms presented?
- What would have made the process smoother?
Disclaimer
This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed.
This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy. This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.
© 2026 Women’s Health Inquiry Project (WHIP). This article includes original analysis of material from publicly available national sources. It may not be reproduced without permission.
References
- NICE CKS: Premenstrual syndrome.
- RCOG Green-top Guideline No. 48: Management of Premenstrual Syndrome.
- Women’s Health Strategy for England (renewed).
- National Association for Premenstrual Syndromes (NAPS) guidelines.
- NIHR and related menstrual health research summaries.